{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:27:09Z","timestamp":1792553229956,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074423"],"award-info":[{"award-number":["82074423"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005893","name":"China Academy of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["CI2021A00903"],"award-info":[{"award-number":["CI2021A00903"]}],"id":[{"id":"10.13039\/501100005893","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejphar.2023.176170","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T21:58:19Z","timestamp":1699307899000},"page":"176170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Sacubitril\/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"961","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-0459","authenticated-orcid":false,"given":"Yu Jiao","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Bo","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo Ju","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176170_bib1","doi-asserted-by":"crossref","first-page":"mjac028","DOI":"10.1093\/jmcb\/mjac028","article-title":"Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics","volume":"14","author":"Abudureyimu","year":"2022","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2023.176170_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjcard.2021.11.045","article-title":"Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction","volume":"167","author":"Albar","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1073\/pnas.231619298","article-title":"Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo","volume":"99","author":"Antos","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2023.176170_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-021-01270-1","article-title":"Sacubitril\/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness","volume":"20","author":"Aroor","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2023.176170_bib5","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ejhf.2738","article-title":"Health-related quality of life outcomes in PARAGON-HF","volume":"24","author":"Chandra","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ejhf.2703","article-title":"Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jacbts.2020.07.006","article-title":"Differential effects of sacubitril\/valsartan on diastolic function in mice with obesity-related metabolic heart disease","volume":"5","author":"Croteau","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ejphar.2023.176170_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of Sacubitril\/Valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of Sacubitril\/Valsartan on N-Terminal Pro-B-Type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejphar.2023.176170_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","article-title":"Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102148","article-title":"PARP-Inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1\/GSK-3\u03b2 and several PKC isoforms","volume":"9","author":"Deres","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176170_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-023-02764-3","article-title":"Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions","volume":"21","author":"Fauchier","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ejphar.2023.176170_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.304","article-title":"Heart failure with preserved ejection fraction: uncertainties and dilemmas","volume":"17","author":"Ferrari","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jcmg.2015.07.004","article-title":"Cardiac imaging to evaluate left ventricular diastolic function","volume":"8","author":"Flachskampf","year":"2015","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ejphar.2023.176170_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2015.10.022","article-title":"Prognostic Value of Galectin-3 for Adverse outcomes in chronic heart failure","volume":"22","author":"French","year":"2016","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jchf.2021.04.009","article-title":"Integrating high-sensitivity troponin T and sacubitril\/valsartan treatment in HFpEF: the PARAGON-HF trial","volume":"9","author":"Gori","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejphar.2023.176170_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1083\/jcb.151.1.117","article-title":"Glycogen synthase kinase-3\u03b2 is a negative regulator of cardiomyocyte hypertrophy","volume":"151","author":"Haq","year":"2000","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2023.176170_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","article-title":"Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment","volume":"10","author":"Harjunp\u00e4\u00e4","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2023.176170_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2022.2847","article-title":"Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction: a review","volume":"7","author":"Harrington","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejphar.2023.176170_bib20","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2023.176170_bib21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejheart.2008.02.013","article-title":"Celecoxib modulates hypertrophic signaling and prevents load-induced cardiac dysfunction","volume":"10","author":"Jacobshagen","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejphar.2023.176170_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113701","article-title":"Progress and prospects of Sacubitril\/Valsartan: based on heart failure with preserved ejection fraction","volume":"155","author":"Jia","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.176170_bib24","doi-asserted-by":"crossref","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-\u03b21 Signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2023.176170_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41374-019-0320-z","article-title":"Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction","volume":"100","author":"Lang","year":"2020","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejphar.2023.176170_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173120","article-title":"Sacubitril\/valsartan attenuates atrial electrical and structural remodeling in a rabbit model of atrial fibrillation","volume":"881","author":"Li","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176170_bib27","article-title":"Cardioprotective effects of early intervention with sacubitril\/valsartan on pressure overloaded rat hearts","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176170_bib28","doi-asserted-by":"crossref","first-page":"H1301","DOI":"10.1152\/ajpheart.00566.2019","article-title":"Pharmacological blockage of ICAM-1 improves angiotensin II-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes","volume":"317","author":"Lin","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2023.176170_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvaa228","article-title":"Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology","volume":"117","author":"Nagueh","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2023.176170_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the HFpEF paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2023.176170_bib35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1058268","article-title":"Blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding macrophage infiltration","volume":"13","author":"Qiu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176170_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176170_bib38","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study","volume":"142","author":"Sanders-van Wijk","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2023.176170_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib40","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.3390\/ijms22073570","article-title":"Sacubitril\/Valsartan improves diastolic function but not skeletal muscle function in a rat model of HFpEF","volume":"22","author":"Schauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176170_bib41","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baselinedisease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejphar.2023.176170_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2023.176170_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2023.176170_bib44","article-title":"Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"9","author":"Shi","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2023.176170_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116849","article-title":"Ling-Gui-Qi-Hua formula alleviates left ventricular myocardial fibrosis in rats with heart failure with preserved ejection fraction by blocking the transforming growth factor-\u03b21\/Smads signaling pathway","volume":"317","author":"Shi","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2023.176170_bib46","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176170_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (Sacubitril\/Valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease","volume":"24","author":"Suematsu","year":"2018","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib48","first-page":"1081","article-title":"Establishment of a rat model of heart failure with preserved ejection fraction and evaluation of the cardiac structure and function by echocardiography","volume":"30","author":"Tang","year":"2021","journal-title":"Chin. J. Ultrasonogr."},{"key":"10.1016\/j.ejphar.2023.176170_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to Sacubitril\/Valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/cvr\/cvq061","article-title":"Constitutive glycogen synthase kinase-3alpha\/beta activity protects against chronic beta-adrenergic remodeling of the heart","volume":"87","author":"Webb","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2023.176170_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrcardio.2012.158","article-title":"Myofibroblast-mediated mechanisms of pathological remodeling of the heart","volume":"10","author":"Weber","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176170_bib52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2023.176170_bib53","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/ejhf.1945","article-title":"Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction","volume":"22","author":"Yamanaka","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176170_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.825459","article-title":"Blocking VCAM-1 prevents angiotensin II-induced hypertension and vascular remodeling in mice","volume":"13","author":"Yin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176170_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.600953","article-title":"Sacubitril\/Valsartan reduces fibrosis and alleviates high-salt diet-induced HFpEF in rats","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:21:59Z","timestamp":1757978519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923006842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S0014299923006842"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176170","relation":{"is-supplemented-by":[{"id-type":"uri","id":"https:\/\/figshare.com\/s\/529a69e1b5b1716f2013","asserted-by":"subject"}]},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176170"}}